What is the effect of entrectinib in the treatment of non-small cell lung cancer?

Entrectinib (Entrectinib), as a targeted therapy drug, has attracted much attention for its therapeutic effect on ROS1-positive non-small cell lung cancer (NSCLC). Through comprehensive analysis of clinical trial data, we can gain a more comprehensive understanding of the efficacy and safety of entrectinib in the treatment of ROS1-positive NSCLC patients.

An important clinical trial isSTARTRK-2(Study of Tumor-Agnostic Therapy With Entrectinib in Subjects With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements) trial, which is designed to evaluate the therapeutic effect of entrectinib on a variety of solid tumors, including ROS1-positive NSCLC. The following is a comprehensive analysis of the test results:

1.ROS1PositiveNSCLC Overall response rate (ORR): In the STARTRK-2 trial, the overall response rate was approximately 77.4% in patients with ROS1-positive NSCLC treated with entrectinib. This means that the majority of patients show a positive clinical response to the drug.

2.Sustained response time (DOR): The patient's sustained response time is a key indicator of the duration of treatment effect. In the STARTRK-2 trial, for those ROS1-positive NSCLC patients who showed a response to entrectinib, the median duration of response was more than two years. This suggests that entrectinib may provide durable efficacy in some patients.

3.Progression-free survival time (PFS): Progression-free survival time is another important clinical endpoint, which reflects the time it takes for a patient's disease to progress after receiving treatment. The STARTRK-2 trial showed that the median progression-free survival time of ROS1positive NSCLC patients was approximately 19.0 months. This suggests that entrectinib can significantly prolong the time to disease progression in patients.

4.Safety: In theSTARTRK-2 trial, entrectinib showed relatively good safety and tolerability. Common adverse reactions include fatigue, nausea, vomiting, mild visual impairment, and mild liver function abnormalities. However, these adverse effects are usually manageable and rarely lead to treatment interruption or cessation.

Taken together, entrectinib, as a targeted therapy for ROS1positiveNSCLC, has demonstrated significant efficacy and relatively good safety in clinical trials. Most patients show positive clinical responses to the drug, with long-lasting responses and prolonged progression-free survival. Although some patients may experience some adverse effects, these are usually manageable. Therefore, entrectinib has potential clinical application in the treatment of ROS1-positive NSCLC patients and provides an effective treatment option for this patient population.

Entrectinib is now available in China and included in the medical insurance system, and patients can purchase it domestically. However, it is quite expensive, costing about 20,000 yuan. For specific price information and medical insurance reimbursement details, patients are advised to consult their local hospital pharmacy for accurate information. In comparison, the price of foreign generic entrectinib drugs is relatively affordable, especially the generic drugs produced in Laos, which only cost about one to two thousand yuan. It is worth mentioning that the ingredients of these generic drugs are basically the same as those of the original drugs. Therefore, patients can choose a suitable treatment plan based on their own financial situation and doctor’s recommendations.